REPL
Replimune Group Inc.
Company Overview
| Mkt Cap | $673.04M | Price | $9.20 |
| Volume | 1.70M | Change | +2.11% |
| P/E Ratio | -2.7 | Open | $8.98 |
| Revenue | -- | Prev Close | $9.01 |
| Net Income | $-247.3M | 52W Range | $2.68 - $15.12 |
| Div Yield | N/A | Target | $11.50 |
| Overall | 63 | Value | 60 |
| Quality | -- | Technical | 66 |
No chart data available
About Replimune Group Inc.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Latest News
Replimune Group Reports Increased Losses Amid R&D Expansion
Replimune’s RP2 Study: A Promising Step in Cancer Immunotherapy
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | REPL | $9.20 | +2.1% | 1.70M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |